LONDON, Sept. 28, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Molecular Cytogenetics in US$ Thousand by the following Technologies: Fluorescence In Situ Hybridization, Array-based Technology. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as -
Abbott Molecular, Inc.
Agilent Technologies, Inc.
Affymetrix, Inc.
Applied Spectral Imaging
Biological Industries
Download the full report: https://www.reportbuyer.com/product/3915706/
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Definitions.............. I-3 Fluorescence In Situ Hybridization (FISH) I-3 Select FISH Procedures in Use I-4 3D-FISH.............. I-4 Cellular Compartment Analysis of Temporal Activity I-4 Combined Binary Ratio-FISH I-4 Cryo-FISH.............. I-4 Immuno-FISH.............. I-4 Quantum Dot-Conjugates-FISH..............I-5 Array-based Technology..............I-5 Array-based Comparative Genomic Hybridization (aCGH) I-5
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 Advanced Molecular Biology Techniques Broaden the Scope of Cytogenetics.............. II-1 Major Growth Drivers..............II-3 Market Outlook.............. II-3 Nucleic Acid Diagnostics Market - An Overview II-4 Molecular Cytogenetics Greatly Benefit Cancer Prognosis II-5 Diverse Applications of FISH Technology in Oncology II-6 Opportunity Indicators: Global Cancer Incidence on the Rise II-6 Table 1: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart) II-6
Table 2: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).............. II-7
Table 3: New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart) II-8
Table 4: Global Cancer Incidence by Income Group: 2012 (in Thousands) (includes corresponding Graph/Chart) II-8 Increasing Significance of Cytogenetic Analysis in Genetic Disease Diagnosis..............II-9 Array-based Technologies to Drive Significant Market Growth II-10 Transition from FISH to Array Based Technologies: A Major Trend II-10 Array-based CGH to Emerge as First Line Test for Clinical Diagnosis of Chromosomal Anomalies II-11 Molecular Cytogenetics Find Increasing Penetration in Clinical Pathological Testing..............II-11 Enhanced AP LIS a Must to Keep Pace with Advancing Molecular Cytogenetic Testing..............II-11 Impact of Shifting Focus of Biopharmaceuticals from Research to Development on Microarray Technology II-11 Next-Gen Sequencing to Challenge Microarray Technology in the Distant Future.............. II-12 Technological Innovations Set to Drive the Market II-12 Role of Molecular Cytogenetics in Personalized Medicine II-13 Improving Healthcare Expenditure Turbo Charges Demand II-14 Table 5: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart) II-14
Table 6: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart)..............II-15 Demographics Spell Growth Opportunities II-15 Table 7: Percentage Breakdown of Global Population by Age Group: 2015, 2050, and 2100 (includes corresponding Graph/Chart).............. II-16
Table 8: 60+ Years Individuals as a Percentage of Total Population in Major Countries Worldwide: 2015, 2050, and 2100 (includes corresponding Graph/Chart) II-17
2. TECHNOLOGY OVERVIEW..............II-18 A Preface to Cytogenetics..............II-18 Basic Terms and Definitions in Molecular Biology II-18 DNA and RNA.............. II-18 RNA (Ribose nucleic acid)..............II-19 Chromosomes.............. II-19 Gene.............. II-19 Genotype.............. II-20 Phenotype.............. II-20 Haplotype.............. II-20 Karyotyping.............. II-20 Karyotype.............. II-20 Nick.............. II-20 Probe.............. II-21 Reporter Molecule..............II-21 Copy Number.............. II-21 Copy Number Variation..............II-21 Analysis of Copy Numbers Variations II-21 Chromosomal Abnormalities in Human Beings II-21 An Overview of Select Chromosomal Anomalies II-22 Insertion.............. II-22 Deletion.............. II-22 Duplication.............. II-22 Rearrangement.............. II-22 Select Human Diseases/Abnormalities Arising due to Translocations II-23 Molecular Cytogenetics: Definition and Scope II-23 Application of Molecular Cytogenetics II-24 Insight into Molecular Cytogenetics Techniques II-24 Fluorescence in situ Hybridization (FISH) II-24 What is In Situ Hybridization? II-24 How is FISH Better than Conventional Techniques? II-25 Fluorescence In Situ Hybridization: The Process II-26 Probe Types and Application..............II-27 Types of Probes..............II-27 Common Methods of Probe Preparation II-27 Nick Translation and Polymerase Chain Reaction (PCR) II-27 Applications of FISH..............II-28 Types of FISH.............. II-28 3D-FISH.............. II-28 ACM-FISH or Multicolor FISH..............II-28 ArmFISH.............. II-29 Catalyzed Reporter Deposition-FISH II-29 Cellular Compartment Analysis of Temporal Activity II-29 Cytochalasin-B -FISH..............II-29 Combined Binary Ratio-FISH..............II-29 Chromosome Orientation And Direction FISH II-30 Combinatorial Oligonucleotide -FISH II-30 Comet-FISH.............. II-30 Cryo-FISH.............. II-30 Double-Fusion -FISH..............II-31 DNA Breakage Detection -FISH..............II-31 e-FISH.............. II-31 Fiber-FISH.............. II-31 Flow-FISH.............. II-31 Fusion-Signal FISH.............. II-32 Halo-FISH.............. II-32 Harlequin-FISH.............. II-32 Immuno-FISH.............. II-32 Locked Nucleic Acids-FISH..............II-33 M-FISH.............. II-33 Multilocus-FISH.............. II-33 Premature Chromosome Condensation-FISH II-33 Peptide Nucleic Acids-FISH..............II-34 Novel FISH Technology to Detect Plague Bacillus II-34 Quantitative-FISH..............II-34 Quantum Dot-Conjugates-FISH..............II-35 Rainbow-FISH.............. II-35 Reverse-FISH.............. II-35 Recognition of Individual Genes-FISH II-35 Expression-FISH.............. II-35 RxFISH.............. II-36 Split-Signal FISH..............II-36 Telomere-FISH/ Tissue-FISH/ Tyramide-FISH (T-FISH) II-36 Zoo-FISH.............. II-36 Spectral Karyotyping (SKY) Technique II-36 Mouse FISH - a New Development..............II-37 Comparative Genomic Hybridization II-37 CGH: The Process.............. II-38 CGH: Applications In Clinical Cytogenetics II-38 Benefits of CGH Analysis in Clinical Genetics II-38 Limitations of CGH.............. II-39 Advent of Microarray Technology..............II-39 What are Microarrays?..............II-39 Microarrays in Gene Expression Analysis II-39 Microarrays in Comparative Genomic Hybridization II-40 Principle Underlying aCGH..............II-40 Low Resolution and High Resolution aCGH II-40 ACGH: The Process..............II-40 aCGH: Potential Uses and Limitations II-41 Potential Advantages of aCGH could be summarized as below II-41 Limitations of aCGH..............II-41 Analytical and Post-analytical Limitations II-41 Interpretation of Results..............II-42 Applications of Acgh..............II-42 A Review of Molecular Biology Techniques in Cytogenetics II-43
3. PRODUCT LAUNCHES/APPROVALS..............II-44 NeoGenomics Introduces NeoSITE Cervical assay to FISH Testing Menu.............. II-44 Oxford Gene Technology Expands Cytocell FISH Probe Portfolio II-44 Applied Spectral Imaging Receives Approval for GenASIs HiPath Platform.............. II-44 Agilent Technologies Introduces OneSeq II-44 Leica Biosystems and Affymetrix Launch ViewRNA™ eZ Assays on BOND RX Platform.............. II-44 Affymetrix and BioDiscovery Launch Cancer Research Software II-44 AKESOgen Launches Cytogenomics Microarray Test II-45 Oxford Gene Technology Launches CytoSure™ Consortium Cancer + SNP array.............. II-45
4. RECENT INDUSTRY ACTIVITY..............II-46 Eurofins Scientific to Acquire Stake in Emory Genetics Laboratory II-46 ESPERITE Acquires Inkaryo..............II-46 Medivo Collaborates with NeoGenomics for Data Analytics II-46 Affymetrix Enters into Agreement with CollabRx II-46 Thermo Fisher Scientific Completes Acquisition of Life Technologies.............. II-46 Applied Spectral Imaging Signs Distribution Partnership with Biocare.............. II-46 Applied Spectral Imaging and BioDot Enter Into Marketing Agreement.............. II-47 Cancer Genetics Italia Enters into Distribution Agreement with Nikon Instruments S.p.A...............II-47 Applied Spectral Imaging Enters Into Agreement with WaveSense II-47 Oxford Gene Technology Signs License Agreement with CCMC II-47
5. FOCUS ON SELECT PLAYERS..............II-48 Abbott Molecular, Inc. (US)..............II-48 Agilent Technologies, Inc. (US)..............II-48 Affymetrix, Inc. (US)..............II-49 Applied Spectral Imaging (US)..............II-49 Biological Industries (Israel) II-50 Bio-Rad Laboratories, Inc. (US)..............II-50 CytoTest, Inc. (US).............. II-51 Cytognomix, Inc. (Canada)..............II-51 Illumina, Inc. (US).............. II-52 Leica Biosystems Nussloch GmbH (Germany) II-52 Oxford Gene Technology (UK)..............II-53 PerkinElmer, Inc. (US)..............II-54 Roche NimbleGen, Inc. (US)..............II-54 SciGene Corporation (US)..............II-54 Thermo Fisher Scientific, Inc. (US) II-55
6. GLOBAL MARKET PERSPECTIVE..............II-56 Table 9: World Recent Past Current & Future Analysis for Molecular Cytogenetics Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-56
Table 10: World Historic Review for Molecular Cytogenetics Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-57
Table 11: World 14-Year Perspective for Molecular Cytogenetics Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-58 By Technology.............. II-59 Table 12: World Recent Past Current & Future Analysis for Fluorescence In Situ Hybridization (FISH) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-59
Table 13: World Historic Review for Fluorescence In Situ Hybridization (FISH) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-60
Table 14: World 14-Year Perspective for Fluorescence In Situ Hybridization (FISH) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-61
Table 15: World Recent Past Current & Future Analysis for Array-Based Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-62
Table 16: World Historic Review for Array-Based Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-63
Table 17: World 14-Year Perspective for Array-Based Technology by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. II-64
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Market Trends.............. III-1 aCGH to Predominate the Technological Front in Molecular Cytogenetics in Future..............III-1 Revised ACMG Guidelines to Accelerate Use of aCGH Over FISH III-1 The Clinical Sector: A Potential Market Opportunity for Array-based Technologies..............III-1 FISH in the Cancer Diagnostics Scenario in the US III-1 Market Restraints.............. III-1 Immunohistochemical (IHC) Tests: The Most Recommended Diagnostic Test for Cancers..............III-1 Factors Limiting the Growth of FISH Technology in Cancer Diagnostics.............. III-2 FISH in Diagnosis of Bladder Carcinoma III-2 FISH in Breast Cancer Diagnosis III-2 Cancer Statistics - Opportunity Indicator III-2 Table 18: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart) III-3
Table 19: Incidence of Cancer for All Body Sites by Gender & Age Group in the US (2013): New Cancer Cases for Males & Females for the Age groups Under 45 years; 45 years and Above; Under 65 years; 65 years and Above (includes corresponding Graph/Chart)..............III-4
Table 20: The US Breast Cancer Incidence in Women by State (2013): New Cases of Breast Cancer in Leading 15 States (includes corresponding Graph/Chart) III-5 Product Launches..............III-5 Strategic Corporate Developments III-6 Focus on Select Major Players..............III-7 B.Market Analytics..............III-13 Table 21: The US Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-13
Table 22: The US Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-14
Table 23: The US 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-15
2. CANADA.............. III-16 A.Market Analysis.............. III-16 Cancer Statistics in Canada: Opportunity Indicator III-16 Table 24: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart) III-16
Table 25: New Cancer Cases in Canada by Province: 2014E (includes corresponding Graph/Chart) III-17
Table 26: New Cancer Cases in Canada by Age Group: 2014E (includes corresponding Graph/Chart) III-18 Cytognomix Inc. - A Key Canadian Player III-18 B.Market Analytics..............III-19 Table 27: Canadian Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-19
Table 28: Canadian Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-20
Table 29: Canadian 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Salesfor Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-21
3. JAPAN.............. III-22 Market Analysis.............. III-22 Table 30: Japanese Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-22
Table 31: Japanese Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-23
Table 32: Japanese 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 009, 2016 & 2022 (includes corresponding Graph/Chart) III-24
4. EUROPE.............. III-25 A.Market Analysis.............. III-25 Cancer Statistics in Europe..............III-25 Table 33: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart) III-25 B.Market Analytics..............III-26 Table 34: European Recent Past Current & Future Analysis for Molecular Cytogenetics by Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-26
Table 35: European Historic Review for Molecular Cytogenetics by Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-27
Table 36: European 14-Year Perspective for Molecular Cytogenetics by Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............III-28
Table 37: European Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-29
Table 38: European Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-30
Table 39: European 14-Year Perspective for Molecular Cytogenetics Market by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-31
4a. FRANCE.............. III-32 Market Analysis.............. III-32 Table 40: French Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-32
Table 41: French Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-33
Table 42: French 14-Year Perspective for Molecular Cytogenetics Market by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-34
4b. GERMANY.............. III-35 A.Market Analysis.............. III-35 Leica Biosystems Nussloch GmbH - A Key Germany-based Player III-35 B.Market Analytics..............III-36 Table 43: German Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-36
Table 44: German Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-37
Table 45: German 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-38
4c. ITALY.............. III-39 A.Market Analysis.............. III-39 Strategic Corporate Development III-39 B.Market Analytics..............III-40 Table 46: Italian Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-40
Table 47: Italian Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Independently Markets Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-41
Table 48: Italian 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-42
4d. THE UNITED KINGDOM..............III-43 A.Market Analysis.............. III-43 Product Launch.............. III-43 Strategic Corporate Development III-43 Oxford Gene Technology - A Key UK-Based Player III-43 B.Market Analytics..............III-44 Table 49: The United Kingdom Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-44
Table 50: The United Kingdom Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-45
Table 51: The United Kingdom 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes correspondingGraph/Chart) III-46
4e. SPAIN.............. III-47 Market Analysis.............. III-47 Table 52: Spanish Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-47
Table 53: Spanish Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-48
Table 54: Spanish 14-Year Perspective for Molecular Cytogenetics Market by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-49
4f. RUSSIA.............. III-50 Market Analysis.............. III-50 Table 55: Russian Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-50
Table 56: Russian Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-51
Table 57: Russian 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009,2016 & 2022 (includes corresponding Graph/Chart) III-52
4g. REST OF EUROPE.............. III-53 A.Market Analysis.............. III-53 Strategic Corporate Developments III-53 B.Market Analytics..............III-54 Table 58: Rest of Europe Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-54
Table 59: Rest of Europe Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-55
Table 60: Rest of Europe 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-56
5. ASIA-PACIFIC.............. III-57 Market Analysis.............. III-57 Table 61: Asia-Pacific Recent Past Current & Future Analysis for Molecular Cytogenetics by Region - China, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-57
Table 62: Asia-Pacific Historic Review for Molecular Cytogenetics by Region - China, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-58
Table 63: Asia-Pacific 14-Year Perspective for Molecular Cytogenetics by Region - Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-59
Table 64: Asia-Pacific Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-60
Table 65: Asia-Pacific Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-61
Table 66: Asia-Pacific 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-62
5a. CHINA.............. III-63 A.Market Analysis.............. III-63 China: A Potential Market for FISH Technology in Clinical Diagnostics.............. III-63 B.Market Analytics..............III-64 Table 67: Chinese Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-64
Table 68: Chinese Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-65
Table 69: Chinese 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-66
5b. REST OF ASIA-PACIFIC..............III-67 A.Market Analysis.............. III-67 An Insight into the Indian Microarray Market III-67 Product Launch.............. III-67 B.Market Analytics..............III-68 Table 70: Rest of Asia-Pacific Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-68
Table 71: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-69
Table 72: Rest of Asia-Pacific 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-70
6. REST OF WORLD.............. III-71 A.Market Analysis.............. III-71 Biological Industries - A Key Israel-based Player III-71 B.Market Analytics..............III-72 Table 73: Rest of World Recent Past Current & Future Analysis for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-72
Table 74: Rest of World Historic Review for Molecular Cytogenetics by Technology Type - Fluorescence in Situ Hybridization and Array-based Technology Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-73
Table 75: Rest of World 14-Year Perspective for Molecular Cytogenetics by Technology Type - Percentage Breakdown of Dollar Sales for Fluorescence in Situ Hybridization and Array-based Technology Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-74
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 27 (including Divisions/Subsidiaries - 28)
The United States (20) Canada (1) Europe (6) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (1)
Download the full report: https://www.reportbuyer.com/product/3915706/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article